Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

Andreu Òdena(Vall d'Hebron Institute of Oncology), Violeta Serra(Vall d'Hebron Institut de Recerca)

npj Precision Oncology

November 21, 2025

10.1038/s41698-025-01172-5

Cited by 0

Related Papers

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

|Oncogene|2011|534

Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

|Cancer Research|2022|94

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

|Genome Medicine|2024|58